ASX - By Stock
|
NUZ |
Re:
Ann: Phase IIb Dog Trial Achieves Interim Clinical Endpoints
|
|
UKTrader54
|
132 |
32K |
9 |
30/06/21 |
30/06/21 |
ASX - By Stock
|
132
|
32K
|
9
|
|
ASX - By Stock
|
DXB |
Re:
Smart money has offloaded
|
|
UKTrader54
|
37 |
16K |
3 |
30/06/21 |
30/06/21 |
ASX - By Stock
|
37
|
16K
|
3
|
|
Charts
|
NUZ Biotech |
Re:
PHARMAUST ALL SET FOR ELY LILLY T/O
|
|
UKTrader54
|
272 |
83K |
12 |
30/06/21 |
30/06/21 |
Charts
|
272
|
83K
|
12
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
UKTrader54
|
75 |
19K |
9 |
30/06/21 |
30/06/21 |
ASX - By Stock
|
75
|
19K
|
9
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Update of DMX-200 Study in COVID-19 Patients in India
|
|
UKTrader54
|
62 |
23K |
4 |
29/06/21 |
29/06/21 |
ASX - By Stock
|
62
|
23K
|
4
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Phase IIb Dog Trial Achieves Interim Clinical Endpoints
|
|
UKTrader54
|
132 |
32K |
6 |
29/06/21 |
29/06/21 |
ASX - By Stock
|
132
|
32K
|
6
|
|
ASX - By Stock
|
IIQ |
Re:
Chart Thread
|
|
UKTrader54
|
1.4K |
562K |
2 |
28/06/21 |
28/06/21 |
ASX - By Stock
|
1.4K
|
562K
|
2
|
|
ASX - By Stock
|
NUZ |
Re:
PAA news and media
|
|
UKTrader54
|
14 |
2.6K |
17 |
28/06/21 |
28/06/21 |
ASX - By Stock
|
14
|
2.6K
|
17
|
|
ASX - By Stock
|
IIQ |
Re:
20% Party
|
|
UKTrader54
|
9 |
5.4K |
1 |
25/06/21 |
25/06/21 |
ASX - By Stock
|
9
|
5.4K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Ann: EU Regulatory Guidance for ATH434 Phase 2 Clinical Trial
|
|
UKTrader54
|
16 |
6.7K |
5 |
23/06/21 |
23/06/21 |
ASX - By Stock
|
16
|
6.7K
|
5
|
|
ASX - By Stock
|
NUZ |
Re:
Seventy Reason to Buy PAA
|
|
UKTrader54
|
273 |
69K |
7 |
23/06/21 |
23/06/21 |
ASX - By Stock
|
273
|
69K
|
7
|
|
ASX - By Stock
|
ALA |
Re:
Ann: Trading Halt
|
|
UKTrader54
|
35 |
9.8K |
0 |
22/06/21 |
22/06/21 |
ASX - By Stock
|
35
|
9.8K
|
0
|
|
ASX - By Stock
|
NUZ |
Re:
Seventy Reason to Buy PAA
|
|
UKTrader54
|
273 |
69K |
3 |
22/06/21 |
22/06/21 |
ASX - By Stock
|
273
|
69K
|
3
|
|
ASX - By Stock
|
NUZ |
Re:
Seventy Reason to Buy PAA
|
|
UKTrader54
|
273 |
69K |
14 |
22/06/21 |
22/06/21 |
ASX - By Stock
|
273
|
69K
|
14
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity
|
|
UKTrader54
|
732 |
151K |
11 |
18/06/21 |
18/06/21 |
ASX - By Stock
|
732
|
151K
|
11
|
|
ASX - By Stock
|
ALA |
Re:
Ann: SUDA Licenses a Novel iNKT Cell Therapy Platform
|
|
UKTrader54
|
35 |
12K |
3 |
18/06/21 |
18/06/21 |
ASX - By Stock
|
35
|
12K
|
3
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity
|
|
UKTrader54
|
732 |
151K |
18 |
18/06/21 |
18/06/21 |
ASX - By Stock
|
732
|
151K
|
18
|
|
ASX - By Stock
|
NUZ |
Re:
Seventy Reason to Buy PAA
|
|
UKTrader54
|
273 |
69K |
12 |
15/06/21 |
15/06/21 |
ASX - By Stock
|
273
|
69K
|
12
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Confirms Phase 3 FSGS Study Design With EMA
|
|
UKTrader54
|
40 |
11K |
1 |
10/06/21 |
10/06/21 |
ASX - By Stock
|
40
|
11K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Confirms Phase 3 FSGS Study Design With EMA
|
|
UKTrader54
|
40 |
11K |
3 |
10/06/21 |
10/06/21 |
ASX - By Stock
|
40
|
11K
|
3
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity
|
|
UKTrader54
|
732 |
151K |
7 |
10/06/21 |
10/06/21 |
ASX - By Stock
|
732
|
151K
|
7
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
UKTrader54
|
22K |
7.9M |
5 |
10/06/21 |
10/06/21 |
ASX - By Stock
|
22K
|
7.9M
|
5
|
|
ASX - By Stock
|
1AI |
Re:
Ann: Business Update
|
|
UKTrader54
|
29 |
13K |
2 |
10/06/21 |
10/06/21 |
ASX - By Stock
|
29
|
13K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Confirms Phase 3 FSGS Study Design With EMA
|
|
UKTrader54
|
40 |
11K |
2 |
09/06/21 |
09/06/21 |
ASX - By Stock
|
40
|
11K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Speculative M&A Transaction Analysis
|
|
UKTrader54
|
854 |
315K |
6 |
09/06/21 |
09/06/21 |
ASX - By Stock
|
854
|
315K
|
6
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity
|
|
UKTrader54
|
732 |
151K |
12 |
04/06/21 |
04/06/21 |
ASX - By Stock
|
732
|
151K
|
12
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity
|
|
UKTrader54
|
732 |
151K |
11 |
03/06/21 |
03/06/21 |
ASX - By Stock
|
732
|
151K
|
11
|
|
ASX - By Stock
|
NUZ |
Re:
Top 20 as at 31 May 2021
|
|
UKTrader54
|
13 |
2.7K |
7 |
03/06/21 |
03/06/21 |
ASX - By Stock
|
13
|
2.7K
|
7
|
|
ASX - By Stock
|
CHM |
Re:
Australian Story
|
|
UKTrader54
|
3 |
1.8K |
3 |
03/06/21 |
03/06/21 |
ASX - By Stock
|
3
|
1.8K
|
3
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust receives ethics approval for Phase I trial in MND
|
|
UKTrader54
|
67 |
15K |
8 |
03/06/21 |
03/06/21 |
ASX - By Stock
|
67
|
15K
|
8
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix Confirms Phase 3 FSGS Study Design With EMA
|
|
UKTrader54
|
40 |
11K |
2 |
03/06/21 |
03/06/21 |
ASX - By Stock
|
40
|
11K
|
2
|
|
ASX - By Stock
|
NUZ |
Re:
Top 20 as at 31 May 2021
|
|
UKTrader54
|
13 |
2.7K |
6 |
03/06/21 |
03/06/21 |
ASX - By Stock
|
13
|
2.7K
|
6
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Contract to Commence Phase 2 Extramedullary AML Trial
|
|
UKTrader54
|
160 |
44K |
5 |
02/06/21 |
02/06/21 |
ASX - By Stock
|
160
|
44K
|
5
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust receives ethics approval for Phase I trial in MND
|
|
UKTrader54
|
67 |
15K |
28 |
02/06/21 |
02/06/21 |
ASX - By Stock
|
67
|
15K
|
28
|
|
ASX - By Stock
|
ATX |
Re:
Ann: AMP945 Improves Survival in Pacnreatic Cancer Model
|
|
UKTrader54
|
49 |
15K |
5 |
02/06/21 |
02/06/21 |
ASX - By Stock
|
49
|
15K
|
5
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: R&D Tax Incentive Refund Received
|
|
UKTrader54
|
12 |
5.3K |
1 |
01/06/21 |
01/06/21 |
ASX - By Stock
|
12
|
5.3K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
valuation thoughts
|
|
UKTrader54
|
380 |
180K |
6 |
01/06/21 |
01/06/21 |
ASX - By Stock
|
380
|
180K
|
6
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
Onward and Upward , MPL vs Covid Trial Results Pending .....
|
|
UKTrader54
|
114 |
24K |
3 |
01/06/21 |
01/06/21 |
ASX - By Stock
|
114
|
24K
|
3
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
Onward and Upward , MPL vs Covid Trial Results Pending .....
|
|
UKTrader54
|
114 |
24K |
10 |
31/05/21 |
31/05/21 |
ASX - By Stock
|
114
|
24K
|
10
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity
|
|
UKTrader54
|
732 |
151K |
11 |
28/05/21 |
28/05/21 |
ASX - By Stock
|
732
|
151K
|
11
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Managing Director and CEO increases shareholding in Imugene
|
|
UKTrader54
|
137 |
58K |
15 |
28/05/21 |
28/05/21 |
ASX - By Stock
|
137
|
58K
|
15
|
|
ASX - By Stock
|
IBX |
Re:
Ann: First-in-human study update - First patient enrolled
|
|
UKTrader54
|
529 |
187K |
3 |
27/05/21 |
27/05/21 |
ASX - By Stock
|
529
|
187K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
UKTrader54
|
75 |
19K |
4 |
26/05/21 |
26/05/21 |
ASX - By Stock
|
75
|
19K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
UKTrader54
|
75 |
19K |
5 |
26/05/21 |
26/05/21 |
ASX - By Stock
|
75
|
19K
|
5
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity
|
|
UKTrader54
|
732 |
151K |
6 |
26/05/21 |
26/05/21 |
ASX - By Stock
|
732
|
151K
|
6
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity
|
|
UKTrader54
|
732 |
151K |
1 |
25/05/21 |
25/05/21 |
ASX - By Stock
|
732
|
151K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
UKTrader54
|
75 |
19K |
4 |
25/05/21 |
25/05/21 |
ASX - By Stock
|
75
|
19K
|
4
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
Covi-Pantel . NZ Trader Release
|
|
UKTrader54
|
1.4K |
321K |
4 |
25/05/21 |
25/05/21 |
ASX - By Stock
|
1.4K
|
321K
|
4
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: BARD1 Demonstrates Feasibility of SubB2M-Based IHC Test
|
|
UKTrader54
|
82 |
32K |
1 |
25/05/21 |
25/05/21 |
ASX - By Stock
|
82
|
32K
|
1
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: BARD1 Demonstrates Feasibility of SubB2M-Based IHC Test
|
|
UKTrader54
|
82 |
32K |
1 |
25/05/21 |
25/05/21 |
ASX - By Stock
|
82
|
32K
|
1
|
|